Welcome to our dedicated page for Soligenix news (Ticker: SNGX), a resource for investors and traders seeking the latest updates and insights on Soligenix stock.
Soligenix, Inc. (NASDAQ: SNGX) is repeatedly described in its public communications as a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. News about SNGX often centers on progress across its two segments, Specialized BioTherapeutics and Public Health Solutions, and provides updates on clinical trials, regulatory designations, advisory boards and financing activities.
In the Specialized BioTherapeutics segment, recent press releases highlight the ongoing confirmatory Phase 3 FLASH2 study of HyBryte™ (SGX301, synthetic hypericin sodium) for cutaneous T-cell lymphoma (CTCL), including enrollment milestones and interim safety reviews. Additional news covers Phase 2a clinical results for SGX302 in mild-to-moderate psoriasis, emphasizing improvements in standard psoriasis indices with synthetic hypericin-based photodynamic therapy, and publications and regulatory designations for SGX945 (dusquetide) in Behçet's Disease, including orphan drug designation from the FDA.
Coverage of Soligenix also includes updates on its innate defense regulator (IDR) technology platform, describing dusquetide’s role in modulating the innate immune response, and on its Public Health Solutions programs such as the RiVax® ricin toxin vaccine candidate, filovirus vaccines and CiVax™ for COVID-19, which use the ThermoVax® heat-stabilization platform and have received support from agencies like NIAID, DTRA and BARDA.
Investors following SNGX news can expect announcements about clinical trial milestones, peer-reviewed publications, FDA orphan and fast track designations, medical advisory board expansions in CTCL, as well as capital markets events such as public offerings and Nasdaq listing compliance updates. Bookmarking the SNGX news page on Stock Titan can help track these developments in one place as the company advances its rare-disease and biodefense pipeline.
Soligenix (NASDAQ: SNGX) is advancing its HyBryte™ platform to address the growing need for treatments in rare diseases, specifically targeting cutaneous T-cell lymphoma (CTCL), a rare skin cancer affecting primarily older adults. The company has successfully established U.S.-based manufacturing for HyBryte's active ingredient.
This development aligns with healthcare initiatives aimed at improving treatment access and accelerating medical innovation, particularly relevant as over 30 million Americans live with rare diseases. The company's focus on CTCL represents a strategic move to address an underserved therapeutic area, especially significant given the aging American population and the challenges in diagnosing rare diseases in seniors.
Soligenix (NASDAQ: SNGX) has announced positive results from its Phase 2a clinical trial of SGX945 (dusquetide) for treating Behçet's Disease. The study demonstrated biological efficacy comparable to the approved drug apremilast (Otezla®), showing a 40% improvement in oral ulcers versus placebo after 4 weeks of treatment.
Key findings include sustained improvement even 4 weeks after treatment cessation, with 7 out of 8 patients reporting benefits. Unlike apremilast, which requires continuous administration and has side effects like diarrhea (41%), nausea (19%), and headache (14%), SGX945 showed no treatment-related adverse events. The company plans to reformulate SGX945 for subcutaneous home-based treatment and proceed with a placebo-controlled Phase 2 study.
Soligenix (Nasdaq: SNGX) provided a corporate update highlighting key developments and upcoming milestones. The company's late-stage rare disease pipeline includes HyBryte™ for cutaneous T-cell lymphoma (CTCL), with top-line results from the 80-patient Phase 3 FLASH2 trial expected in H2 2026. The trial has shown promising results with 75% treatment success after 18 weeks of continuous treatment.
Additional pipeline developments include SGX302 for psoriasis with Phase 2a results expected in Q4 2025, and SGX945 for Behçet's Disease with Phase 2a results anticipated in Q3 2025. The company projects potential peak annual U.S. sales of $90 million for HyBryte™, with a total addressable global market of over $2B across all programs. Soligenix reports approximately $7 million in cash, providing runway into Q1 2026.
Soligenix (Nasdaq: SNGX) has successfully completed the transfer of synthetic hypericin manufacturing from Europe to the United States through its partnership with Sterling Pharma Solutions. The manufacturing process transfer includes optimization and implementation of a commercially viable, scalable production process for the active ingredient used in HyBryte™ and SGX302 formulations.
The synthetic hypericin is being developed for treating cutaneous T-cell lymphoma (CTCL) and psoriasis. The companies have established cGMP manufacturing capabilities for clinical trials and are working towards a long-term commercial manufacturing collaboration. Sterling's expertise includes innovative solutions such as continuous flow chemistry for this product.
Soligenix (SNGX) announced positive interim results from an FDA-funded study evaluating extended HyBryte™ treatment for early-stage cutaneous T-cell lymphoma (CTCL). After 18 weeks of treatment, 75% of patients achieved Treatment Success, defined as ≥50% improvement in mCAILS score.
Of the eight evaluable patients through Week 18, four completed the 54-week treatment with an average maximum improvement of 85% in mCAILS score, three remain on treatment, and one dropped out due to logistical issues. The study, led by Dr. Ellen Kim at Penn Cutaneous Lymphoma Program, demonstrates HyBryte's™ rapid response compared to other CTCL therapies that typically take 6-12 months for meaningful results.
The ongoing open-label study aims to enroll approximately 20 patients, supported by an FDA Orphan Products Development Grant of up to $2.6 million. The results reinforce HyBryte's™ potential as a safe and fast-acting therapy for this rare cancer.
Soligenix (NASDAQ: SNGX) has published preclinical efficacy results for CiVax™, their thermostabilized subunit vaccine against SARS-CoV-2. The study demonstrated that combining a primary adenovirus vaccine (COVID-19 Vaccine AstraZeneca) with a CiVax™ booster induced broader protection against COVID-19 variants in non-human primates compared to a traditional 2-shot mRNA vaccination series.
The research, conducted in collaboration with Dr. Axel Lehrer from the University of Hawaiʻi, showed that CiVax™ generates rapid-onset multi-variant booster responses when used in a heterologous prime-boost approach. A key advantage of CiVax™ is its thermostability, allowing ambient temperature shipping and requiring only sterile water reconstitution before use.
The vaccine leverages Soligenix's ThermoVax® platform, which has successfully stabilized vaccines for ricin toxin and filoviruses. This technology enhances standard protein subunit vaccination, potentially offering a safer alternative that doesn't require strict cold-storage requirements like mRNA vaccines.
Soligenix (SNGX) reported its financial results for the year ended December 31, 2024, with a net loss of $8.3 million ($4.98 per share) compared to $6.1 million in 2023. Revenue decreased to $0.1 million from $0.8 million in the previous year.
The company maintains $7.8 million in cash, providing operational runway through 2025. Research and development expenses increased to $5.2 million from $3.3 million, while general and administrative expenses decreased to $4.2 million from $4.5 million.
Key developments include patient enrollment for the confirmatory Phase 3 study of HyBryte™ in CTCL treatment, with top-line results expected in 2026. Additionally, top-line results from Phase 2 studies for SGX945 in Behçet's disease and SGX302 in psoriasis are anticipated in the second half of 2025.
Soligenix (NASDAQ: SNGX) announced upcoming presentations of their HyBryte™ (synthetic hypericin) treatment studies at two major medical conferences in March 2025. The presentations will showcase data from recent supportive trials in cutaneous T-cell lymphoma (CTCL) and psoriasis treatments.
The findings will be presented at the United States Cutaneous Lymphoma Consortium (USCLC) Workshop on March 6 and the American Academy of Dermatology (AAD) Annual Meeting from March 7-11 in Orlando, Florida. Dr. Ellen Kim from Penn Cutaneous Lymphoma Program will present results from an ongoing investigator-initiated study on HyBryte™'s long-term CTCL treatment, while Dr. Neal Bhatia will discuss topical and photodynamic therapy considerations at AAD.
The presentations will include findings from recent supportive studies demonstrating longer treatment efficacy, minimal systemic hypericin exposure after topical application, and comparative efficacy against Valchlor®.